{"ctNumber":"2024-518608-28-00","ctStatus":"Authorised","startDateEU":"2025-05-01","decisionDate":"2025-04-13T20:13:39.294","publishDate":"2026-09-17T03:33:14.56305632","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":144097,"rowSubjectCount":0,"products":[{"id":601932,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625894","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284058","marketingAuthNumber":"EU/1/22/1685/052","prodAuthStatus":2,"prodName":"Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625894","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284058","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601933,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB12581MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SODIUM CHLORIDE","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"SODIUM CHLORIDE","euSubstNumber":"SUB12581MIG","productSubstances":[{"substancePk":"385277","actSubstOrigin":"Chemical","actSubstName":"SODIUM CHLORIDE","substanceEvCode":"SUB12581MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each."},"isPaediatricFormulation":false,"mpRoleInTrial":"3","orphanDrugEdit":false,"doseUom":"ml millilitre(s)","maxDailyDoseAmount":"0.43","doseUomTotal":"ml millilitre(s)","maxTotalDoseAmount":"72","productChangedRelationMA":false,"maxTreatmentPeriod":24,"timeUnitCode":"2","otherMedicinalProduct":"sodium chloride, placebo","scientificProductEvCode":"SUB12581MIG","devices":[],"characteristics":["11"],"routes":["SUBCUTANEOUS INJECTION"],"allSubstancesChemicals":false,"productName":"SODIUM CHLORIDE","jsonActiveSubstanceNames":"sodium chloride"},{"id":601930,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11697530","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284056","marketingAuthNumber":"EU/1/22/1685/050","prodAuthStatus":2,"prodName":"Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11697530","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284056","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601928,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625902","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284066","marketingAuthNumber":"EU/1/22/1685/060","prodAuthStatus":2,"prodName":"Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625902","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284066","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601929,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625896","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284060","marketingAuthNumber":"EU/1/22/1685/054","prodAuthStatus":2,"prodName":"Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625896","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284060","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601931,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11644464","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284064","marketingAuthNumber":"EU/1/22/1685/058","prodAuthStatus":2,"prodName":"Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11644464","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284064","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601927,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625898","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284062","marketingAuthNumber":"EU/1/22/1685/056","prodAuthStatus":2,"prodName":"Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625898","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284062","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Effect of tirzepatide on alcohol intake and reward processing in patients diagnosed with schizophrenia and alcohol use disorder","fullTitleTranslations":[],"publicTitle":"Can treatment with tirzepatide reduce alcohol intake in individuals diagnosed with schizophrenia and alcohol use disorder (DUALPSYCHIATRY)","publicTitleTranslations":[{"id":12242512,"uuid":"418056e4-c446-47e8-8766-2ded4e86930e","attributeTranslation":"KAN BEHANDLING MED TIRZEPATID REDUCERE ALKOHOLINDTAGET BLANDT PERSONER DIAGNOSTICERET MED SKIZOFRENI OG ALKOHOLAFHÆNGIGHED? (DUALPSYCHIATRY)","language":3,"languageDescription":"'Danish"}],"secondaryIdentifyingNumbers":{"whoUniversalTrialNumber":{"id":580095,"number":"U1111-1312-8134"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"This trial is carried out for exploration of new indication for an existing product that already has a marketing authorisation.","trialCategoryId":133400},"medicalCondition":{"partIMedicalConditions":[{"id":151170,"medicalCondition":"Schizophrenia and Alcohol Use Disorder","medicalConditionTranslations":[{"id":12242511,"uuid":"eb7b3c42-7897-467c-baa7-e781c4380139","attributeTranslation":"Skizofreni og alkoholafhængighedssyndrom","language":3,"languageDescription":"'Danish"}],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"3","trialScopeId":438781},{"code":"5","trialScopeId":438783},{"code":"4","trialScopeId":438782}],"mainObjective":"This study will examine the effects of tirzepatide vs. placebo on alcohol consumption in patients diagnosed with schizophrenia and alcohol use disorder.","mainObjectiveTranslations":[],"secondaryObjectives":[]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":983190,"number":1,"principalInclusionCriteria":"Informed Consent: The patient must provide both oral and written informed consent.","principalInclusionCriteriaTranslations":[]},{"id":983191,"number":2,"principalInclusionCriteria":"Diagnosis:  o\tDiagnosed with alcohol dependence according to the International Classification of Diseases, 10th Edition (ICD-10), and alcohol use disorder as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). o\tDiagnosed with schizophrenia spectrum disorder according to ICD-10 and DSM-5","principalInclusionCriteriaTranslations":[]},{"id":983192,"number":3,"principalInclusionCriteria":"AUDIT Score: Alcohol Use Disorder Identification Test (AUDIT) score greater than 15.","principalInclusionCriteriaTranslations":[]},{"id":983193,"number":4,"principalInclusionCriteria":"Body Mass Index (BMI): BMI of 23 kg/m² or higher.","principalInclusionCriteriaTranslations":[]},{"id":983194,"number":5,"principalInclusionCriteria":"Age Range: Between 18 and 70 years old (inclusive).","principalInclusionCriteriaTranslations":[]},{"id":983195,"number":6,"principalInclusionCriteria":"Heavy Alcohol Consumption: Defined as 4 or more heavy drinking days within a consecutive 21-day period during the 28 days preceding the baseline evaluation. The 21-day period will be selected based on the largest total alcohol consumption and the greatest number of heavy drinking days within the 28-day timeframe. This will be assessed using the Timeline Followback (TLFB) method. Heavy drinking days are defined as days with an alcohol intake of 4 or more units (48 g of alcohol) for women and 5 or more units (60 g of alcohol) for men.","principalInclusionCriteriaTranslations":[]}],"principalExclusionCriteria":[{"id":1678290,"number":1,"principalExclusionCriteria":"-\tIntellectual Disability: individuals with a diagnosis of intellectual disability.","principalExclusionCriteriaTranslations":[]},{"id":1678291,"number":10,"principalExclusionCriteria":"-\tLiver Function: Impaired hepatic function, defined as liver transaminases greater than three times the upper limit of normal.","principalExclusionCriteriaTranslations":[]},{"id":1678292,"number":11,"principalExclusionCriteria":"-\tRenal Function: Impaired renal function, indicated by an estimated glomerular filtration rate (eGFR) below 50 mL/min and/or plasma creatinine above 150 μmol/L.","principalExclusionCriteriaTranslations":[]},{"id":1678293,"number":12,"principalExclusionCriteria":"-\tPancreatic Function: History of acute or chronic pancreatitis or amylase levels more than twice the upper limit of normal.","principalExclusionCriteriaTranslations":[]},{"id":1678294,"number":13,"principalExclusionCriteria":"-\tThyroid Conditions: Previous medullary thyroid carcinoma (MTC) or a family history of MTC and/or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).","principalExclusionCriteriaTranslations":[]},{"id":1678295,"number":14,"principalExclusionCriteria":"-\tCardiac Issues: Decompensated heart failure (NYHA class III or IV), unstable angina pectoris, or myocardial infarction within the past 12 months.","principalExclusionCriteriaTranslations":[]},{"id":1678296,"number":15,"principalExclusionCriteria":"-\tUncontrolled Hypertension: Systolic blood pressure above 180 mmHg or diastolic blood pressure above 110 mmHg.","principalExclusionCriteriaTranslations":[]},{"id":1678297,"number":16,"principalExclusionCriteria":"-\tAlcohol Use Disorder Medication: Use of medications for alcohol use disorder (e.g., disulfiram, naltrexone, acamprosate, nalmefene) within the 28 days prior to inclusion as recorded in the Timeline Followback (TLFB) schedule.","principalExclusionCriteriaTranslations":[]},{"id":1678298,"number":17,"principalExclusionCriteria":"-\tInvestigational Drugs: Receipt of any investigational drug within the past three months.","principalExclusionCriteriaTranslations":[]},{"id":1678299,"number":18,"principalExclusionCriteria":"-\tWeight-Lowering Medications: Use of other weight-lowering pharmacotherapy, including tirzepatide or other GLP-1 RA, in the past three months.","principalExclusionCriteriaTranslations":[]},{"id":1678300,"number":19,"principalExclusionCriteria":"-\tAllergic Reactions: Hypersensitivity to the active substance or any of the excipients.","principalExclusionCriteriaTranslations":[]},{"id":1678301,"number":2,"principalExclusionCriteria":"-\tAcute Psychosis: Acute exacerbation of psychosis, Severe acute exacerbation of psychosis, as assessed by the investigator during clinical evaluation","principalExclusionCriteriaTranslations":[]},{"id":1678302,"number":20,"principalExclusionCriteria":"-\tLanguage Barriers: Inability to speak and/or understand Danish.","principalExclusionCriteriaTranslations":[]},{"id":1678303,"number":21,"principalExclusionCriteria":"-\tOther Conditions: Any other condition that, in the investigator's opinion, may interfere with participation in the trial.","principalExclusionCriteriaTranslations":[]},{"id":1678304,"number":22,"principalExclusionCriteria":"For the subgroup of participants undergoing brain scans: -\tMRI Contraindications: any contraindications for MRI (e.g., magnetic implants, pacemaker, claustrophobia). -\tBenzodiazepine Use: Intermittent use of benzodiazepines within 12 days prior to the scanning session is not allowed. However, regular use of a stable dose of benzodiazepines is permitted.","principalExclusionCriteriaTranslations":[]},{"id":1678305,"number":3,"principalExclusionCriteria":"-\tCoercive Measures: Current use of coercive measures, which includes individuals sentenced to treatment (‘dom til behandling’).","principalExclusionCriteriaTranslations":[]},{"id":1678306,"number":4,"principalExclusionCriteria":"-\tSuicidal Behaviour: Evidence of current severe suicidal behaviour, as assessed by the investigator during clinical evaluation.","principalExclusionCriteriaTranslations":[]},{"id":1678307,"number":5,"principalExclusionCriteria":"-\tHistory of Severe Alcohol Withdrawal: History of delirium tremens or alcohol withdrawal seizures.","principalExclusionCriteriaTranslations":[]},{"id":1678308,"number":6,"principalExclusionCriteria":"-\tSevere Withdrawal Symptoms: Clinical Institute Withdrawal Assessment of Alcohol Scale, revised (CIWA-Ar) score greater than 9 at baseline examination.","principalExclusionCriteriaTranslations":[]},{"id":1678309,"number":7,"principalExclusionCriteria":"-\tSevere Neurological Conditions: Presence of severe neurological diseases, including severe traumatic brain injury.","principalExclusionCriteriaTranslations":[]},{"id":1678310,"number":8,"principalExclusionCriteria":"-\tDiabetes: Type 1 or 2 diabetes","principalExclusionCriteriaTranslations":[]},{"id":1678311,"number":9,"principalExclusionCriteria":"-\tPregnant or potentially pregnant women: Women of childbearing potential (WOCBP) who are pregnant, breastfeeding, intend to become pregnant within the next eight months (including 26 weeks of treatment plus two months after discontinuation of tirzepatide), or are not using a highly effective contraceptive method throughout the study period. Highly effective methods include combined hormonal contraception (oral, intravaginal, transdermal), progestogen-only hormonal contraception (oral, injectable, implantable), intrauterine device (IUD), intrauterine system (IUS), bilateral tubal occlusion, vasectomised partner, or sexual abstinence. WOCBP with a measured serum human chorionic gonadotropin (hCG) level greater than 3 U/L at inclusion will also be excluded","principalExclusionCriteriaTranslations":[]}]},"endPoint":{"primaryEndPoints":[{"id":1149108,"number":1,"endPoint":"The primary endpoint will be a change in alcohol consumption, measured as a per cent change in heavy drinking days (days with an excess alcohol intake of 60 grams for men and 48 grams for women) after 16 weeks of treatment with tirzepatide or placebo, adjusted for the value at baseline (percentage points). Heavy drinking days will be registered using the validated Timeline-Follow-Back (TLFB) method.","isPrimary":true,"endPointTranslations":[]}],"secondaryEndPoints":[{"id":1149109,"number":1,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in total alcohol consumption measured using the TLFB method","isPrimary":false,"endPointTranslations":[]},{"id":1149110,"number":2,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in number of days without alcohol measured using the TLFB method.","isPrimary":false,"endPointTranslations":[]},{"id":1149111,"number":3,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in World Health Organisation (WHO) alcohol risk level measured using the TLFB method.","isPrimary":false,"endPointTranslations":[]},{"id":1149112,"number":4,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in alcohol craving score using the Penn Alcohol Craving Scale (PACS) score.","isPrimary":false,"endPointTranslations":[]},{"id":1149113,"number":5,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in Alcohol Use Disorders Identification Test (AUDIT)-score","isPrimary":false,"endPointTranslations":[]},{"id":1149114,"number":6,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in Drug Use Disorders Identification Test (DUDIT)-score","isPrimary":false,"endPointTranslations":[]},{"id":1149115,"number":7,"endPoint":"Changes from baseline to after 26 weeks of treatment in quality of life measured using the Schizophrenia Quality of Life Scale (SQLS)","isPrimary":false,"endPointTranslations":[]},{"id":1149116,"number":8,"endPoint":"Changes from baseline to after 26 weeks of treatment in Clinical Global Impression Severity Scale (CGI-S)","isPrimary":false,"endPointTranslations":[]},{"id":1149117,"number":9,"endPoint":"Changes from baseline to after 26 weeks of treatment in Global Assessment of Psychosocial Disability (GAPD)","isPrimary":false,"endPointTranslations":[]},{"id":1149118,"number":10,"endPoint":"Changes from baseline to after 26 weeks of treatment in symptom severity of schizophrenia measured using the six-item Positive and Negative Syndrome Scale (PANSS-6)","isPrimary":false,"endPointTranslations":[]},{"id":1149119,"number":11,"endPoint":"Changes from baseline to after 16 and after 26 weeks of treatment in the Patient Health Questionnaire (PHQ-9) score","isPrimary":false,"endPointTranslations":[]},{"id":1149120,"number":12,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in smoking habits using the Fagerströms Test for Nicotine Dependence score","isPrimary":false,"endPointTranslations":[]},{"id":1149121,"number":13,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in blood parameters (GGT, ALAT, MCV)","isPrimary":false,"endPointTranslations":[]},{"id":1149122,"number":14,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in blood phosphatidyl ethanol (PEth) levels","isPrimary":false,"endPointTranslations":[]},{"id":1149123,"number":15,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in body weight and waist circumference","isPrimary":false,"endPointTranslations":[]},{"id":1149124,"number":16,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in blood pressure and pulse","isPrimary":false,"endPointTranslations":[]},{"id":1149125,"number":17,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in glycemic parameters (HbA1c)","isPrimary":false,"endPointTranslations":[]},{"id":1149126,"number":18,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in risk of liver fibrosis measured using the FIB-4 index","isPrimary":false,"endPointTranslations":[]},{"id":1149127,"number":19,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in proteomics","isPrimary":false,"endPointTranslations":[]},{"id":1149128,"number":20,"endPoint":"For a subgroup of participants (n=50), fMRI will be conducted at baseline and after 16 weeks of treatment to evaluate:  Changes in fMRI BOLD signals in response to alcohol cues in brain regions related to reward and mood and changes in resing state fMRI","isPrimary":false,"endPointTranslations":[]},{"id":1149129,"number":21,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in blood cotinine levels","isPrimary":false,"endPointTranslations":[]},{"id":1149130,"number":22,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in average number of cigarettes smoked per day","isPrimary":false,"endPointTranslations":[]},{"id":1149131,"number":23,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in preferred substance of use","isPrimary":false,"endPointTranslations":[]},{"id":1149132,"number":24,"endPoint":"For a subgroup of participants (n=10), qualitative interviews will be performed after 16 weeks of treatment to evaluate qualitative differences in trial participation experiences between the intervention and placebo groups, which will be assessed as a secondary outcome.","isPrimary":false,"endPointTranslations":[]},{"id":1149133,"number":25,"endPoint":"Changes in biomarkers of recent cannabis exposure (blood 11-hydroxy-delta 9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH) levels) from baseline to after 16 and 26 weeks of treatment","isPrimary":false,"endPointTranslations":[]},{"id":1149134,"number":26,"endPoint":"Changes from baseline to after 26 weeks of treatment in per cent heavy drinking days assessed using the TLFB method","isPrimary":false,"endPointTranslations":[]},{"id":1149135,"number":27,"endPoint":"Changes from baseline to after 16 weeks and after 26 weeks of treatment in the drug use frequency section of the DUDIT-extended","isPrimary":false,"endPointTranslations":[]}]},"trialDuration":{"estimatedEndDate":"2028-12-31","estimatedRecruitmentStartDate":"2025-03-01"},"sourceOfMonetarySupport":[{"id":106274,"organisationName":"The Novo Nordisk Foundation"},{"id":106275,"organisationName":"The Danish Independent Research Fund"}],"populationOfTrialSubjects":{"ageRanges":[{"id":396237,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":396238,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"1","planDescription":"IPD will be shared when all data is anonymized or de-identified to protect participants' privacy and in accordance with relevant regulations (GDPR). IPD will only be shared upon reasonable relevant requests, e.g.  for meta-analyses or independent validations."}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-16","conclusionDate":"2026-09-16","therapeuticAreas":[{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}],"medicalConditions":[{"id":151170,"medicalCondition":"Schizophrenia and Alcohol Use Disorder","isConditionRareDisease":false}],"sponsors":[{"id":164323,"primary":true,"publicContacts":[{"id":485241,"type":"Public","functionalName":"Søren Brøgger Jensen","functionalEmailAddress":"soeren.broegger.jensen@regionh.dk","telephone":"+4560294963","organisation":{"id":649394,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Psykiatrisk Center Kobenhavn","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100031006","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":485242,"type":"Scientific","functionalName":"Søren Brøgger Jensen","functionalEmailAddress":"soeren.broegger.jensen@regionh.dk","telephone":"+4560294963","organisation":{"id":649394,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Psykiatrisk Center Kobenhavn","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100031006","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":753889,"organisationAddress":{"id":679893,"organisation":{"id":717996,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Aalborg University Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022335","organisationLocationStatus":"Active"},"address":{"addressId":741196,"oneLine":"Sdr, Søndre Skovvej 15","addressLine1":"Sdr","addressLine2":"Søndre Skovvej 15","addressLine3":"","addressLine4":"","city":"Aalborg","postcode":"9000","country":2009,"countryName":"Denmark"},"phone":"+4521531349","email":"gcp@rn.dk","isBusinessKeyValidated":true,"businessKey":"ORG-100022335"},"sponsorDuties":[{"id":1167335,"code":"1"}],"phoneNumber":"+4521531349","email":"gcp@rn.dk"},{"id":753891,"organisationAddress":{"id":679845,"organisation":{"id":717948,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Aalborg University Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022335","organisationLocationStatus":"Active"},"address":{"addressId":741138,"oneLine":"Moelleparkvej 10","addressLine1":"Moelleparkvej 10","addressLine2":"","addressLine3":"","addressLine4":"","city":"Aalborg","postcode":"9000","country":2009,"countryName":"Denmark"},"phone":"+4528722962","email":"ren@rn.dk","isBusinessKeyValidated":true,"businessKey":"ORG-100022335"},"sponsorDuties":[{"id":1167337,"code":"2"}],"phoneNumber":"+4528722962","email":"ren@rn.dk"},{"id":753890,"organisationAddress":{"id":618027,"organisation":{"id":655897,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Frederiksberg Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028217","organisationLocationStatus":"Active"},"address":{"addressId":668051,"oneLine":"Nordre Fasanvej 57, 1st Floor Entrance 2","addressLine1":"Nordre Fasanvej 57","addressLine2":"1st Floor Entrance 2","addressLine3":"","addressLine4":"","city":"Frederiksberg","postcode":"2000","country":2009,"countryName":"Denmark"},"phone":"+4538635620","email":"gcp-enheden.bispebjerg-frederiksberg-hospitaler@regionh.dk","isBusinessKeyValidated":true,"businessKey":"ORG-100028217"},"sponsorDuties":[{"id":1167336,"code":"1"}],"phoneNumber":"+4538635620","email":"gcp-enheden.bispebjerg-frederiksberg-hospitaler@regionh.dk"}],"organisation":{"id":1083746,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Hovedstaden","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"},"addresses":[{"id":1036319,"organisation":{"id":1083746,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Hovedstaden","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"},"address":{"addressId":1171098,"oneLine":"Nordre Fasanvej 57, 1st Floor Entrance 2","addressLine1":"Nordre Fasanvej 57","addressLine2":"1st Floor Entrance 2","addressLine3":"","addressLine4":"","city":"Frederiksberg","postcode":"2000","country":2009,"countryName":"Denmark"},"isBusinessKeyValidated":true,"businessKey":"LOC-100045259"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"This trial is carried out for exploration of new indication for an existing product that already has a marketing authorisation.","partOneTherapeuticAreas":[{"id":1247198,"therapeuticArea":{"code":"33","name":"Psychiatry and Psychology [F] - Mental Disorders [F03]"}}],"productRoleGroupInfos":[{"id":446185,"comments":"SODIUM CHLORIDE","productRoleCode":"3","productRoleName":"Placebo","products":[{"id":601933,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB12581MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SODIUM CHLORIDE","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"SODIUM CHLORIDE","euSubstNumber":"SUB12581MIG","productSubstances":[{"substancePk":"385277","actSubstOrigin":"Chemical","actSubstName":"SODIUM CHLORIDE","substanceEvCode":"SUB12581MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":"pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each."},"isPaediatricFormulation":false,"mpRoleInTrial":"3","orphanDrugEdit":false,"doseUom":"ml millilitre(s)","maxDailyDoseAmount":"0.43","doseUomTotal":"ml millilitre(s)","maxTotalDoseAmount":"72","productChangedRelationMA":false,"maxTreatmentPeriod":24,"timeUnitCode":"2","otherMedicinalProduct":"sodium chloride, placebo","scientificProductEvCode":"SUB12581MIG","devices":[],"characteristics":["11"],"routes":["SUBCUTANEOUS INJECTION"],"allSubstancesChemicals":false,"productName":"SODIUM CHLORIDE","jsonActiveSubstanceNames":"sodium chloride"}]},{"id":446184,"comments":"Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen","productRoleCode":"1","productRoleName":"Test","products":[{"id":601927,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625898","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284062","marketingAuthNumber":"EU/1/22/1685/056","prodAuthStatus":2,"prodName":"Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625898","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284062","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601928,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625902","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284066","marketingAuthNumber":"EU/1/22/1685/060","prodAuthStatus":2,"prodName":"Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625902","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284066","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601929,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625896","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284060","marketingAuthNumber":"EU/1/22/1685/054","prodAuthStatus":2,"prodName":"Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625896","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284060","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601930,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11697530","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284056","marketingAuthNumber":"EU/1/22/1685/050","prodAuthStatus":2,"prodName":"Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11697530","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284056","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601931,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11644464","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284064","marketingAuthNumber":"EU/1/22/1685/058","prodAuthStatus":2,"prodName":"Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11644464","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284064","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"},{"id":601932,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11625894","productPharmForm":"SOLUTION FOR INJECTION IN PRE-FILLED PEN","euMpNumber":"PRD11284058","marketingAuthNumber":"EU/1/22/1685/052","prodAuthStatus":2,"prodName":"Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"TIRZEPATIDE","euSubstNumber":"SUB198055","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005620","nameOrg":"ELI LILLY NEDERLAND B.V.","productSubstances":[{"productPk":"11625894","substancePk":"371479","nameOrg":"ELI LILLY NEDERLAND B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"TIRZEPATIDE","substanceEvCode":"SUB198055","synonyms":["LY3298176","LY-3298176","L-TYROSYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L- .ALPHA.-ASPARTYL-L-TYROSYL-L-SERYL-L-ISOLEUCYL-2-METHYLALANYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-L-LYSYL-LISOLEUCYL- L-ALANYL-L-GLUTAMINYL-N6-((22S)-22,42-DICARBOX"]}],"atcCode":"A10BX","atcName":"OTHER ORAL BLOOD GLUCOSE LOWERING DRUGS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2.14","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"240","productChangedRelationMA":false,"maxTreatmentPeriod":26,"timeUnitCode":"2","evCode":"PRD11284058","devices":[],"characteristics":[],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":false,"productName":"Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen","jsonActiveSubstanceNames":"tirzepatide","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":249007,"mscId":40494,"mscInfo":{"id":40494,"clinicalTrialId":19781,"countryOrganisationId":2009,"reportingStatusCode":"Authorised","fromDate":"2025-03-26","toDate":"2025-03-26","isProposedRms":true,"countryName":"Denmark","organisationInfo":{},"firstDecisionDate":"2025-04-13","trialStatus":"Authorised","trialPeriod":[{"id":55883,"trialStartDate":"2025-05-01","fromDate":"2025-05-02"},{"id":55884,"trialStartDate":"2025-05-01","fromDate":"2025-05-02"},{"id":55882,"trialStartDate":"2025-05-01","fromDate":"2025-05-02"}],"trialRecruitmentPeriod":[{"id":75687,"recruitmentStartDate":"2025-05-05","fromDate":"2025-05-07"},{"id":75688,"recruitmentStartDate":"2025-05-05","fromDate":"2025-05-07"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":81102,"trialStartDate":"2025-05-01","fromDate":"2025-05-02"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-05-05"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":73489,"mscId":40494,"trialStatus":"Under evaluation","trialStatusDate":"2025-01-10T11:10:38.337"},{"id":80592,"mscId":40494,"trialStatus":"Authorised","trialStatusDate":"2025-04-13T20:13:38.724"}],"applicationTypeMsc":"1","mscName":"Denmark","decision":"authorized","decisionDate":"2025-04-13"},"decisionDate":"2025-04-13","recruitmentSubjectCount":108,"trialSites":[{"id":1696178,"organisationAddressInfo":{"id":680194,"organisation":{"id":718300,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Frederiksberg Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028217","organisationLocationStatus":"Active"},"address":{"addressId":741566,"oneLine":"Nordre Fasanvej 57, 1st Floor Entrance 2","addressLine1":"Nordre Fasanvej 57","addressLine2":"1st Floor Entrance 2","addressLine3":"","addressLine4":"","city":"Frederiksberg","postcode":"2000","country":2009,"countryName":"Denmark"},"phone":"+4522755843","email":"anders.fink-jensen@regionh.dk","isBusinessKeyValidated":true,"businessKey":"ORG-100028217"},"personInfo":{"id":1885686,"firstName":"Anders","lastName":"Fink-Jensen","telephone":"+4522755843","email":"anders.fink-jensen@regionh.dk","title":"2"},"departmentName":"Lab of Neuropsychiatry"},{"id":1696177,"organisationAddressInfo":{"id":680181,"organisation":{"id":718287,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Region Nordjylland","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100045768","organisationLocationStatus":"Active"},"address":{"addressId":741551,"oneLine":"Moelleparkvej 10","addressLine1":"Moelleparkvej 10","addressLine2":"","addressLine3":"","addressLine4":"","city":"Aalborg","postcode":"9000","country":2009,"countryName":"Denmark"},"phone":"28722962","email":"ren@rn.dk","isBusinessKeyValidated":true,"businessKey":"ORG-100045768"},"personInfo":{"id":1885685,"firstName":"Rene","lastName":"Nielsen","telephone":"28722962","email":"ren@rn.dk","title":"2"},"departmentName":"Psychiatric Research Unit"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":37144,"type":"INITIAL","status":"Authorised","ctNumber":"2024-518608-28-00","trialStatus":"Authorised","submissionDate":"2025-01-10","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-14"},"partIIInfo":[{"id":194783,"mscId":40494,"mscInfo":{"id":40494,"mscName":"Denmark","countryOrganisationId":2009,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-04-11","decision":"authorized","decisionDate":"2025-04-13","reportingStatusCode":"Authorised","countryName":"Denmark","trialStatus":"Authorised","firstDecisionDate":"2025-04-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-04-13","ctMSCsByApplication":[{"id":40494,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":66526,"applicationId":37144,"mscId":40494,"mscName":"Denmark","decisionDate":"2025-04-13T20:13:39.294","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":194783,"part1Id":76076,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"01a0af9e-4dc6-49ac-9c07-ba8d4d82f90d","productRoleGroupId":237767}]},{"id":67455,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-518608-28-00","trialStatus":"Authorised","submissionDate":"2026-01-07","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-03-14"},"partIIInfo":[{"id":249007,"mscId":40494,"mscInfo":{"id":40494,"mscName":"Denmark","countryOrganisationId":2009,"decision":"authorized","decisionDate":"2025-04-13","reportingStatusCode":"Authorised","countryName":"Denmark","trialStatus":"Authorised","firstDecisionDate":"2025-04-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-01-07","ctMSCsByApplication":[{"id":40494,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"NSM-4","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":104089,"applicationId":67455,"mscId":40494,"mscName":"Denmark","decisionDate":"2026-01-07T14:28:56.898","decision":"authorized","eventType":"decision","part2Id":249007,"part1Id":103914,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"01a0af9e-4dc6-49ac-9c07-ba8d4d82f90d","productRoleGroupId":323235}]},{"id":94415,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-518608-28-00","trialStatus":"Authorised","submissionDate":"2026-09-14","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-16"},"partIIInfo":[],"decisionDate":"2026-09-16","ctMSCsByApplication":[{"id":40494,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":142176,"applicationId":94415,"mscId":40494,"mscName":"Denmark","decisionDate":"2026-09-16T12:18:55.959","decision":"authorized","eventType":"decision","part1Id":144097,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"01a0af9e-4dc6-49ac-9c07-ba8d4d82f90d","productRoleGroupId":446184}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Denmark","mscId":40494,"firstDecisionDate":"2025-04-13T20:13:39.294","lastDecisionDate":"2026-01-07T14:28:56.898","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":40494,"mscName":"Denmark","events":[{"notificationType":"START_OF_TRIAL","date":"2025-05-01"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-05-05"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"informedconsent_patientrecruitmentprocedure_2024-518608-28","uuid":"724b6e3d-9f7b-4957-aef5-0202a9483072","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"3","systemVersion":"3"},{"title":"K2_Recruitment material_Tekst til RHP research portal","uuid":"0a614d43-c749-402a-8c8e-7ecb232394fc","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"2","systemVersion":"3"},{"title":"K2_Recruitment material_tekst til alkoholforskningdk","uuid":"a3ab4b40-2d1b-413a-80c4-d6a4e0cdb279","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"3","systemVersion":"3"},{"title":"K2_recruitment material_EBOKS invitation","uuid":"20cf3c28-9dbb-43a2-94c7-8a8e21480cd9","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"3","systemVersion":"3"},{"title":"K2_Recruitment material_trialtree_material","uuid":"20c40c27-d006-4ea0-9cff-a0e10b458d76","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"2","systemVersion":"2"},{"title":"K2_Recruitment material_Rekrutteringsplakat","uuid":"af5ad92b-2d0a-46bc-980e-ae6bd9f54f1f","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"3","systemVersion":"3"},{"title":"K2_Recruitment material_Rekrutteringsfolder","uuid":"60193cfc-c11c-4023-967f-92d886994915","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"3","systemVersion":"3"},{"title":"L1_SIS_Deltagerinformation 2024-518608-28","uuid":"0867c1ac-67e7-48a7-8de8-aa3f5530cab9","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"2","systemVersion":"2"},{"title":"L1_ICF_Samtykkeerklring_Biobank_fremtidig forskning 2024-518608-28","uuid":"ae2e913c-0524-4b25-81db-73200b66357f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":249007,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocol 2024-518608-28","uuid":"8fada1f5-7c19-459d-b816-bfbf7b573c74","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":144097,"manualVersion":"3","systemVersion":"3"},{"title":"Alcohol_registration_TLFB_2024-518608-28","uuid":"f240e614-a665-4c13-99c6-7793030b7e29","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"AUDIT_2024-518608-28","uuid":"924240c5-9463-4c6f-afab-87431e8b3c8b","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"DUDIT_2024-518608-28","uuid":"ae578348-59ad-4399-9e88-0de900645d1f","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"PHQ9_Danish for Denmark_2024-518608-28","uuid":"6dc00fef-e7f1-4f7b-b7f0-d4aa87d389ab","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"Questionnaire_PACS_2024-518608-28","uuid":"abeac47e-09fc-49d9-ad7a-20f8a78e7e91","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"Schizophrenia Quality of Life Scale_2024-518608-28","uuid":"538a7979-1d2a-4c53-9d4c-e88d21821b0c","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"Sprgeskema om rygning_2024-518608-28","uuid":"0ba295fa-4e69-4cfc-a329-35e48d3545c7","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"DUDIT-Ed_2024-518608-28","uuid":"e9948c3d-4be8-448a-b747-cc538934dbf6","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"D1_PROTOKOL SYNOPSIS_DA 2024-518608-28","uuid":"71344a88-6e6c-439e-a69a-d01914cbd9da","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":144097,"manualVersion":"1","systemVersion":"1"},{"title":"G2_SmPC Mounjaro","uuid":"01a0af9e-4dc6-49ac-9c07-ba8d4d82f90d","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":446184,"manualVersion":"1","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}